ResMed (RMD) Projected to Post Earnings on Thursday

ResMed (NYSE:RMD) is expected to release its Q1 2026 results after the market closes on Thursday, October 30th. Analysts expect ResMed to post earnings of $2.49 per share and revenue of $1.3332 billion for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earningreport page for the latest details on the call scheduled for Thursday, October 30, 2025 at 4:30 PM ET.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, July 31st. The medical equipment provider reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.47 by $0.08. The firm had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.33 billion. ResMed had a return on equity of 25.62% and a net margin of 27.22%.The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.08 EPS. On average, analysts expect ResMed to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

ResMed Stock Performance

RMD stock opened at $257.10 on Wednesday. The business’s fifty day moving average is $274.14 and its 200-day moving average is $260.31. The company has a quick ratio of 2.53, a current ratio of 3.44 and a debt-to-equity ratio of 0.11. The company has a market cap of $37.52 billion, a P/E ratio of 27.03, a price-to-earnings-growth ratio of 1.79 and a beta of 0.83. ResMed has a twelve month low of $199.92 and a twelve month high of $293.81.

ResMed Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, September 18th. Stockholders of record on Thursday, August 14th were paid a $0.60 dividend. This is an increase from ResMed’s previous quarterly dividend of $0.53. The ex-dividend date of this dividend was Thursday, August 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. ResMed’s dividend payout ratio (DPR) is currently 25.24%.

Insiders Place Their Bets

In other ResMed news, General Counsel Michael J. Rider sold 100 shares of the stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $274.36, for a total transaction of $27,436.00. Following the completion of the transaction, the general counsel owned 11,327 shares in the company, valued at approximately $3,107,675.72. This represents a 0.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director John Hernandez sold 2,575 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $287.10, for a total value of $739,282.50. Following the transaction, the director owned 4,045 shares of the company’s stock, valued at approximately $1,161,319.50. This trade represents a 38.90% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 18,743 shares of company stock worth $5,284,514. Corporate insiders own 0.65% of the company’s stock.

Hedge Funds Weigh In On ResMed

A number of large investors have recently modified their holdings of RMD. Alliancebernstein L.P. boosted its stake in shares of ResMed by 24.2% during the 2nd quarter. Alliancebernstein L.P. now owns 286,078 shares of the medical equipment provider’s stock worth $73,808,000 after buying an additional 55,790 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of ResMed by 13.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 350,417 shares of the medical equipment provider’s stock worth $90,408,000 after buying an additional 40,399 shares during the last quarter. Captrust Financial Advisors boosted its stake in shares of ResMed by 6.2% during the 2nd quarter. Captrust Financial Advisors now owns 510,058 shares of the medical equipment provider’s stock worth $131,595,000 after buying an additional 29,729 shares during the last quarter. Canada Pension Plan Investment Board boosted its stake in shares of ResMed by 141.1% during the 2nd quarter. Canada Pension Plan Investment Board now owns 35,889 shares of the medical equipment provider’s stock worth $9,259,000 after buying an additional 21,005 shares during the last quarter. Finally, Quantinno Capital Management LP boosted its stake in shares of ResMed by 21.4% during the 2nd quarter. Quantinno Capital Management LP now owns 85,204 shares of the medical equipment provider’s stock worth $21,983,000 after buying an additional 15,016 shares during the last quarter. 54.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on RMD. Stifel Nicolaus increased their price target on ResMed from $240.00 to $270.00 and gave the company a “hold” rating in a research note on Friday, August 1st. Citigroup began coverage on ResMed in a research note on Thursday, September 18th. They issued a “buy” rating and a $330.00 price target on the stock. Royal Bank Of Canada increased their price target on ResMed from $294.00 to $300.00 and gave the company an “outperform” rating in a research note on Friday, August 1st. Wall Street Zen downgraded ResMed from a “buy” rating to a “hold” rating in a research note on Sunday, August 10th. Finally, Morgan Stanley upped their price objective on shares of ResMed from $298.00 to $304.00 and gave the company an “overweight” rating in a research report on Tuesday, October 21st. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $295.70.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.